Abstract
There is little known about pharmacogenetic of fluoxetine in children and adolescents. In this study, we evaluate, for the first time, the influence of CYP2D6, CYP2C9 and ABCB1 genotypes on the steady-state plasma concentrations of fluoxetine and its active metabolite (S)-norfluoxetine, and on the clinical improvement in children and adolescent patients receiving fluoxetine treatment. The assessment was performed in 83 patients after 8 and 12 weeks of treatment. Fluoxetine/(S)-norfluoxetine ratio was negatively correlated with the number of active CYP2D6 alleles (r: −0.450; P<0.001). Regarding the G2677T ABCB1 polymorphism, T allele carriers showed significantly higher improvements on the majority of scales including the Clinical Global Impression-Improvement scale (P<0.001). Our results confirm the influence of CYP2D6 genetic variants in fluoxetine pharmacokinetics and provide evidence for the potential effect of the ABCB1 genotype on the clinical improvement in children and adolescent patients treated with fluoxetine.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 print issues and online access
$259.00 per year
only $43.17 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Usala T, Clavenna A, Zuddas A, Bonati M . Randomised controlled trials of selective serotonin reuptake inhibitors in treating depression in children and adolescents: a systematic review and meta-analysis. Eur Neuropsychopharmacol 2008; 18: 62–73.
Keeton CP, Kolos AC, Walkup JT . Pediatric generalized anxiety disorder: epidemiology, diagnosis and management. Paediatr Drugs 2009; 11: 171–183.
Wilens TE, Cohen L, Biederman J, Abrams A, Neft D, Faird N et al. Fluoxetine Pharmacokinetics in pediatric patients. J Clin Psychopharmacol 2002; 22: 568–575.
Blazquez A, Mas S, Plana MT, Lafuente A, Lázaro L . Fluoxetine pharmacogenetics in child and adult populations. Eur Child Adolesc Psychiatry 2012; 21: 599–610.
DeVane CL . Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors. Cell Mol Neurobiol 1999; 19: 443–466.
Hiemke C, Härtter S . Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther 2000; 85: 11–28.
Ring BJ, Eckstein JA, Gillespie JS, Binkley SN, VandenBranden M, Wrighton SA . Identification of the human cytochromes P450 responsible for in vitro formation of R- and S-norfluoxetine. J Pharmacol Exp Ther 2001; 297: 1044–1050.
Sachse C, Brockmöller J, Bauer S, Roots I . Cytochrome P450 2D6 variants in a Causasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60: 284–295.
Rettie AE, Wienkers LC, González FJ, Trager WF, Korzekwa KR . Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994; 4: 39–42.
Haining RL, Hunter AP, Veronese ME, Trager WF, Rettie AE . Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. Arch Biochem Biophys 1996; 333: 447–458.
Uhr M, Grauer MT, Yassouridis A, Ebinger M . Blood-brain barrier penetration and pharmacokinetics of amitriptyline and its metabolites in P-glycoprotein (abcb1ab) knock-out mice and controls. J Psychiatr Res 2007; 41: 179–188.
Uhr M, Grauer MT, Holsboer F . Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption. Biol Psychiatry 2003; 54: 840–846.
Uhr M, Grauer MT . Abcb1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice. J Psychiatr Res 2003; 37: 179–185.
Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, Johne A et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000; 97: 3473–3478.
Eichelbaum M, Fromm MF, Schwab M . Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther Drug Monit 2004; 26: 180–185.
Scordo MG, Spina E, Dahl ML, Gatti G, Perucca E . Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine. Basic Clin Pharmacol Toxicol 2005; 97: 296–301.
Serretti A, Calati R, Massat I, Linotte S, Kasper S, Lecrubier Y et al. Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients. Int Clin Psychopharmacol 2009; 24: 250–256.
Llerena A, Dorado P, Berecz R, González AP, Peñas-Lledó EM . Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions. Eur J Clin Pharmacol 2004; 59: 869–873.
Menu P, Gressier F, Verstuyft C, Hardy P, Becquemont L, Corruble E . Antidepressants and ABCB1 gene C3435T functional polymorphism: a naturalistic study. Neuropsychobiology 2010; 62: 193–197.
Dong C, Wong ML, Licinio J . Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association with major depression and antidepressant response in Mexican-Americans. Mol Psychiatry 2009; 14: 1105–1118.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Press: Washington, DC, 1994.
Llerena A, Dorado P, Berecz R, González A, Norberto JM, de la Rubia A et al. Determination of fluoxetine and norfluoxetine in human plasma by high-performance liquid chromatography with ultraviolet detection in psychiatric patients. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 783: 25–31.
Kovacs M . Children’s Depression Inventory Manual. Multi-Health Systems: New York, 1992.
Foa EB, Coles M, Huppert JD, Pasupuleti RV, Franklin ME, March J . Development and validation of a child version of the obsessive compulsive inventory. Behav Ther 2010; 41: 121–132.
Birmaher B, Khetarpal S, Brent D, Cully M, Balach L, Kaufman J et al. The Screen for Child Anxiety Related Emotional Disorders (SCARED): scale construction and psychometric characteristics. J Am Acad Child Adolesc Psychiatry 1997; 36: 545–553.
Guy W . ECDEU Assessment Manual for Psychopharmacology, Revised. United States Department of Health, Education, and Welfare: Bethesda, MD, 1976.
Luborsky L . Clinician’s judgments of mental health: a proposed scale. Arch Gen Psychiatry 1962; 7: 407–417.
Shaffer D, Gould MS, Brasic J, Ambrosini P, Fisher P, Bird H et al. A children's global assessment scale (CGAS). Arch Gen Psychiatry 1983; 40: 1228–1231.
Lundmark J, Reis M, Bengtsson F . Serum concentrations of fluoxetine in the clinical treatment setting. Ther Drug Monit 2001; 23: 139–147.
Eap CB, Bondolfi G, Zullino D, Savary-Cosendai L, Powell-Golay K, Kosel M et al. Concentrations of the enantiomers of fluoxetine and norfluoxetine after multiple doses of fluoxetine in cytochrome P4502D6 poor and extensive metabolizers. J Clin Psychopharmacol 2001; 21: 330–334.
Charlier C, Broly F, Lhermitte M, Pinto E, Ansseau M, Plomteaux G . Polymorphisms in the CYP2D6 gene: association with plasma concentrations of fluoxetine and paroxetine. Ther Drug Monit 2003; 25: 738–742.
Grasmäder K, Verwohlt PL, Rietschel M, Dragicevic A, Müller M, Hiemke C et al. Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur J Clin Pharmacol 2004; 60: 329–336.
Jannuzzi G, Gatti G, Magni P, Spina E, Pacifici R, Zuccaro P et al. Plasma concentrations of the enantiomers of fluoxetine and norfluoxetine: sources of variability and preliminary observations on relations with clinical response. Ther Drug Monit 2002; 24: 616–627.
Rasmussen BB, Brøsen K . Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther Drug Monit 2000; 22: 143–154.
Gex-Fabry M, Eap CB, Oneda B, Gervasoni N, Aubry JM, Bondolfi G et al. CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response. Ther Drug Monit 2008; 30: 474–482.
Sarginson JE, Lazzeroni LC, Ryan HS, Ershoff BD, Schatzberg AF, Murphy GM Jr. . ABCB1 (MDR1) polymorphisms and antidepressant response in geriatric depression. Pharmacogenet Genomics 2010; 20: 467–475.
Nikisch G, Eap CB, Baumann P . Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: a pilot study. Pharmacol Res 2008; 58: 344–347.
Uhr M, Tontsch A, Namendorf C, Ripke S, Lucae S, Ising M et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron 2008; 57: 203–209.
Kato M, Fukuda T, Serretti A, Wakeno M, Okugawa G, Ikenaga Y et al. ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 398–404.
Uhr M, Steckler T, Yassouridis A, Holsboer F . Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption. Neuropsychopharmacology 2000; 22: 380–387.
Noordam R, Aarts N, Hofman A, van Schaik RH, Stricker BH, Visser LE . Association between genetic variation in the ABCB1 gene and switching, discontinuation, and dosage of antidepressant therapy: results from the Rotterdam Study. J Clin Psychopharmacol 2013; 33: 546–550.
Fujii T, Ota M, Hori H, Sasayama D, Hattori K, Teraishi T et al. Association between the functional polymorphism (C3435T) of the gene encoding P-glycoprotein (ABCB1) and major depressive disorder in the Japanese population. J Psychiatr Res 2012; 46: 555–559.
Kunugi H, Hori H, Adachi N, Numakawa T . Interface between hypothalamic-pituitary-adrenal axis and brain-derived neurotrophic factor in depression. Psychiatry Clin Neurosci 2010; 64: 447–459.
Acknowledgements
This work was supported by the Spanish Ministry of Health, Instituto Carlos III, Fondo de Investigación Sanitaria (FIS) (PI041239 and ‘Sara Borrell’ contract CD09/00296 to PG); the Catalan Innovation, Universities and Enterprise Authority (grants DIUE 2009SGR1295, 2009SGR1501, 2009SGR1119); Alicia Koplowitz Foundation; and FEDER-Unión Europea. We thank Rosa Abellana for help in the statistical analysis, and the Language Advisory Service at the University of Barcelona, Spain, for manuscript revision.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Gassó, P., Rodríguez, N., Mas, S. et al. Effect of CYP2D6, CYP2C9 and ABCB1 genotypes on fluoxetine plasma concentrations and clinical improvement in children and adolescent patients. Pharmacogenomics J 14, 457–462 (2014). https://doi.org/10.1038/tpj.2014.12
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/tpj.2014.12
This article is cited by
-
ABCB1 variants and sex affect serotonin transporter occupancy in the brain
Molecular Psychiatry (2022)
-
Impacts of Cytochrome P450 2D6*10 Allele and a High-Fat Meal on the Pharmacokinetics of Dapoxetine in Healthy Chinese Men: A Single-Dose, Two-Treatment Study
Advances in Therapy (2019)
-
Genetische Tests zur Steuerung der Behandlung mit Antidepressiva
Der Nervenarzt (2017)
-
Constellation: a tool for rapid, automated phenotype assignment of a highly polymorphic pharmacogene, CYP2D6, from whole-genome sequences
npj Genomic Medicine (2016)
-
Serotonin transporter gene (SLC6A4) polymorphisms are associated with response to fluoxetine in south Indian major depressive disorder patients
European Journal of Clinical Pharmacology (2016)